Back to Menu
On the afternoon of September 8, 2025, a delegation led by Professor Charles M. Balch, a globally recognized expert in oncology from the MD Anderson Cancer Center at the University of Texas, United States, visited Jinshazhou Hospital of Guangzhou University of Chinese Medicine for a guided tour and academic exchange. The visit aimed to strengthen international academic communication and collaboration in the field of oncology, conduct an on-site assessment of the hospital's oncology diagnosis and treatment system, and lay a solid foundation for future in-depth cooperation. The hospital president Liu Wenwei, vice president Wang Yang, chief physicist of the International Oncology Diagnosis and Treatment Center Wei Xiaping, and relevant department heads accompanied the visit and participated in discussion sessions.
Founded in 1941, MD Anderson Cancer Center is an internationally renowned institution in oncology diagnosis, treatment, and research. It has consistently led the global development of clinical oncology, basic research, and translational medicine, earning international recognition for its multidisciplinary collaboration, precision treatment technologies, and innovative research systems. Professor Charles Balch, as a core expert at the center, has profound expertise in surgical oncology. He has served as former vice president and CEO of the American Society of Clinical Oncology (ASCO), former president of the Society of Surgical Oncology (SSO), and currently serves as editor-in-chief of Annals of Surgical Oncology, holding significant academic influence in the global oncology community.
During the visit, Professor Balch toured the hospital's Radiation Oncology Center, Multidisciplinary Consultation Center, Imaging Diagnostic Center, and Clinical Research Laboratory. At the Radiation Oncology Center, hospital representatives introduced internationally advanced equipment, including the M6 CyberKnife, and its clinical applications for precision radiotherapy planning in diseases such as lung cancer, breast cancer, and skull-base tumors. Professor Balch highly praised the hospital's model of "advanced equipment, precise treatment, and standardized processes" and showed particular interest in the hospital's integrative oncology rehabilitation system combining traditional Chinese medicine features. He engaged in detailed discussions with accompanying experts on treatment design, efficacy evaluation standards, and other clinical aspects.
During the subsequent discussion session, President Liu Wenwei warmly welcomed Professor Balch on behalf of the hospital and provided a detailed introduction to the hospital's ten-year development history, the five-year achievements of the Oncology Center, talent cultivation efforts, and progress in international cooperation. He emphasized that Jinshazhou Hospital of Guangzhou University of Chinese Medicine has consistently followed the development philosophy of "integrating traditional Chinese and Western medicine with precision oncology." Hosting a world-leading expert such as Professor Balch not only recognizes the hospital's oncology diagnosis and treatment capabilities but also represents an important opportunity to advance the hospital's international development. President Liu expressed hope that the hospital could establish long-term and stable collaboration with MD Anderson Cancer Center in areas including expert exchange, scientific research cooperation, and talent training.
During the discussion, Professor Balch fully recognized the rapid progress made by the hospital in the field of precision oncology. He noted that cancer treatment has entered a new era of "multidisciplinary integration and individualized precision therapy," and that Jinshazhou Hospital of Guangzhou University of Chinese Medicine, through its investment in equipment, technological innovation, and exploration of combined Chinese and Western treatment approaches, is highly aligned with international trends in oncology. Drawing on his own experience in surgical oncology and clinical research design, he offered constructive suggestions on further optimizing multidisciplinary consultation processes, improving the efficiency of scientific research translation, and standardizing clinical data management. He also expressed his willingness to serve as a bridge for academic exchange, supporting the hospital in advancing its oncology diagnosis and treatment to world-class standards.
The visit of Professor Charles M. Balch not only brought the hospital access to cutting-edge international concepts and technical approaches in oncology but also established a platform for dialogue and collaboration with top global cancer centers. Going forward, the hospital plans to use this exchange as an opportunity to deepen international cooperation, incorporate advanced global practices, and continuously enhance its capabilities in precision oncology and research innovation, providing higher-quality and internationally benchmarked medical services to cancer patients across the Guangdong-Hong Kong-Macao Greater Bay Area and throughout China.
